Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects.
The three approved nucleoside analogues are fairly well tolerated, and only a few patients have to discontinue therapy permanently. However, because clinical experience is limited, especially with ddI and ddC, delayed toxicities are likely to emerge over time. In addition, physicians should be vigilant for overlapping toxicities from combination therapy with these and other medications.
Saag
M S
MS
University of Alabama, Birmingham.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D000998:Antiviral Agents / Q000009:adverse effects*; D016049:Didanosine / Q000009:adverse effects; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D016047:Zalcitabine / Q000009:adverse effects; D015215:Zidovudine / Q000009:adverse effects
D000998:Antiviral Agents; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine